



**Figure S2. Distribution of dalbavancin (A), clindamycin (B), moxifloxacin (C) and rifampin (D) MIC values within each non-beta-haemolytic streptococcal group (n=505).**

MIC values were determined by broth microdilution. The dotted lines indicate the EUCAST v 13.0 clinical breakpoints (A, B), and the ECOFFs (C, D), dalbavancin clinical breakpoint being only applicable to isolates of the *anginosus* group.